What Chemical Stability Parameters Govern Intramammary Infusion Formulation of Cloxacillin Sodium?

The intramammary infusion route for bovine mastitis therapy constitutes the highest-volume downstream application for veterinary-grade cloxacillin sodium API. Cloxacillin sodium belongs to the semi-synthetic penicillinase-resistant isoxazolyl penicillin class, and its 3-(2-chlorophenyl)-5-methyl-4-isoxazolyl side chain confers resistance to hydrolysis by staphylococcal β-lactamases of classes A, B, C, and D as classified by the Ambler scheme. This structural attribute positions the API as first-line therapy against penicillinase-producing Staphylococcus aureus and coagulase-negative staphylococci (CNS) recovered from clinical mastitis cases in dairy herds. The sodium salt exhibits aqueous solubility of approximately 1 g in 0.9 mL of water at 20°C, a property that imposes specific handling constraints during formulation, sterile filling, and long-term storage of the finished intramammary product.Degradation in aqueous solution is governed jointly by hydrogen-ion concentration and thermal load. Published stability data for cloxacillin sodium indicate maximum shelf stability at pH 6.0-7.0 and 25°C, with pseudo-first-order degradation rate constants accelerating sharply below pH 4.5 due to acid-catalyzed β-lactam ring opening and above pH 8.0 due to base-catalyzed hydrolysis of the penam bicyclic nucleus. Buffering of aqueous intramammary solutions with phosphate buffer (0.05 M, pH 6.8) or citrate buffer (0.02 M, pH 6.5) is standard industrial practice. Oil-based suspension vehicles—typically refined peanut oil BP, sesame oil USP-NF, or medium-chain triglycerides Ph. Eur.—circumvent aqueous hydrolysis entirely, though partition kinetics, oxidative rancidity of vehicle oils, and sedimentation behavior require separate characterization per Ph. Eur. 2.2.32 (loss on drying) and rheological profiling.Two distinct intramammary formulation archetypes are manufactured from this API grade. Lactating-cow therapy syringes contain cloxacillin sodium equivalent to 200 mg cloxacillin base per 10 mL unit, dispersed or solubilized in a vehicle exhibiting a dynamic viscosity between 150-400 mPa·s at 25°C as measured on a Brookfield LV viscometer (spindle 2, 30 rpm per USP <912>). Dry cow therapy syringes contain the equivalent of 500 mg cloxacillin per 10 mL unit in a slow-release vehicle engineered to maintain intramammary residence through the 42-60 day dry period of the bovine lactation cycle. Aluminum hydroxide di-stearate or hydrogenated castor oil at 2-4 wt% provides thixotropic structuring in oil vehicles, rendering the suspension flowable under syringe-actuation shear while retaining depot behavior after intramammary deposition.Manufacture of intramammary products requires full aseptic processing because cloxacillin sodium is thermolabile in aqueous solution and cannot tolerate terminal steam sterilization at 121°C for 15 min as defined by Ph. Eur. 5.1.1. EU GMP Annex 1 designates Grade A (ISO 5) filling zones with Grade B (ISO 7) background for aseptic connections and open product exposure. Isolator-based filling with hydrogen peroxide vapor (VHP) decontamination cycles of 0.5-1.0 h at 300-400 ppm H₂O₂ is the preferred containment strategy. The API bulk solution is filtered through 0.22 µm PVDF or PES membranes prior to filling, with filtration losses of 5-15% attributable to membrane adsorption at solution concentrations below 5% w/v. Sterility is confirmed per USP <71> (Ph. Eur. 2.6.1) on every batch, and bacterial endotoxins per USP <85> (Ph. Eur. 2.6.14) must not exceed 0.5 EU per syringe. Particulate matter limits per USP <788> apply directly to the intramammary product.Production-scale suspension homogenization for intramammary oil formulations uses rotor-stator high-shear mixers such as the Silverson GX or IKA Ultra-Turrax UTL operating at 5,000-10,000 rpm for 15-30 min, followed by vacuum deaeration at < 50 mbar absolute pressure to remove entrained air bubbles that impair dose accuracy in syringe filling. Solid API dispersion is verified by laser diffraction on a Malvern Mastersizer 3000 with a D90 target below 75 µm to prevent nozzle clogging during insertion into the teat canal. Fill accuracy on multi-lane syringe fillers maintains ±3% of nominal volume across production speeds of 120-200 units/min. Veterinary medicinal product compliance for intramammary cloxacillin requires demonstration of bioequivalence per VICH GL36, referencing EMA/CVMP/VICH/835/99. Milk withholding periods are determined under the Grade A Pasteurized Milk Ordinance (PMO) provisions of the US FDA, with milk discard times typically 48-96 h post-treatment for lactating formulations. Residue depletion studies are performed according to VICH GL49, with cloxacillin as the marker residue in bovine milk at an MRL of 30 µg/kg per EU Regulation 37/2010.

Lyophilized Injection Powders Require Aseptic Fill-Finish Without Terminal Sterilization

Sterile injectable powders for reconstitution represent the second major downstream processing route for this cloxacillin sodium API grade. Because cloxacillin sodium degrades measurably in aqueous solution at ambient temperature, the commercial injectable presentation is a dry powder cake or crystalline fill that is reconstituted at point of use with Sterile Water for Injection (SWFI) or 0.9% Sodium Chloride Injection USP. The reconstitution concentration typically achieves 250 mg cloxacillin per mL, corresponding to the practical solubility limit of the sodium salt under pharmaceutically acceptable pH conditions of 6.0-7.5 post-reconstitution.Lyophilized injectable formulations are prepared by dissolving cloxacillin sodium in Water for Injection at 20-25% w/v along with bulking agents selected for cake stability. Mannitol at 2-5% w/v is preferred because its crystalline habit reduces cake collapse during primary drying, while dextran 40 at 2% w/v is employed when a glassy amorphous matrix with improved redissolution kinetics is required. The lyophilization cycle for a typical 10 mL fill (2.5 g cloxacillin sodium) in 20 mL Type I borosilicate glass vials proceeds as follows: freezing to -45°C at 1.0°C/min ramp rate; primary drying at -20°C shelf temperature and 80-100 mTorr chamber pressure for 18-24 h; secondary drying at 25°C for 6-8 h to reduce residual moisture below 2.0% w/w by Karl Fischer titration per USP <921> Method I. Batch-scale lyophilizers such as the SP Scientific Lyostar III incorporate capacitance manometers and Pirani gauges for comparative pressure measurement, enabling thermocouple-free product temperature monitoring during primary drying.The aseptic fill process for the injectable powder is governed by EU GMP Annex 1 (August 2022 revision) requirements for Grade A (ISO 5) zones with Grade B background. Terminal gamma irradiation or ethylene oxide sterilization is not applicable to cloxacillin sodium injection powders: ionizing radiation induces free-radical degradation of the β-lactam ring at doses as low as 10 kGy, and residual ethylene oxide reacts with the carboxylic acid moiety forming ethylene glycol mono-ester degradants. Sterility of the filled powder is therefore ensured exclusively by sterile filtration of the intermediate bulk solution through 0.22 µm filters (Millipore Durapore PVDF or Sartorius Sartopore 2) prior to lyophilization. Pre-use filter integrity testing by bubble point (≥ 3.2 bar for Durapore 0.22 µm in water) and post-use testing per ASTM F838-20 are mandatory batch release requirements.Bacterial endotoxin specification for intramuscular injectable cloxacillin sodium is ≤ 0.5 EU/mg, and for intravenous administration the limit tightens to ≤ 0.05 EU/mg per USP <85> (Ph. Eur. 2.6.14). API lots failing this specification require depyrogenation via activated carbon treatment at 0.1-0.3% w/v contact for 15-30 min or ultrafiltration with a 10 kDa molecular weight cut-off in tangential flow configuration. Endotoxin recovery studies using the Limulus Amebocyte Lysate (LAL) chromogenic method per Ph. Eur. 2.6.14 Method D must demonstrate absence of assay interference from the API matrix or formulation excipients.Reconstituted solutions at 250 mg/mL have a pH of 6.0-7.5 and an osmolarity of 350-450 mOsm/kg by freezing-point depression osmometry. Chemical stability of reconstituted cloxacillin sodium at 2-8°C is stated as 24 h in most product instructions; published degradation studies from parenteral stability literature indicate approximately 90% of initial potency retained at 24 h at 4°C, dropping to approximately 85% at 6 h at 25°C. No particulate matter should be present after reconstitution; USP <788> limits applied as ≤ 6,000 particles/container ≤ 10 µm and ≤ 600 particles/container ≤ 25 µm for volumes exceeding 100 mL, adjusted proportionally for smaller fills. Intravenous admixtures with 5% Dextrose Injection USP degrade faster than those with 0.9% Sodium Chloride due to the acidic pH (3.5-5.5) of dextrose solutions and should be infused within 2 h of preparation to avoid sub-therapeutic potency.

Tablet and Capsule Excipient Compatibility Under Low-Humidity Direct Compression

Oral solid dosage forms of cloxacillin sodium for companion animals—administered for canine and feline dermatological, respiratory, and soft-tissue infections caused by susceptible β-lactamase-producing staphylococci and streptococci—are manufactured by both direct compression and wet granulation routes. The hygroscopic character of the sodium salt dictates processing environment control at every stage. Dynamic vapor sorption (DVS) analysis demonstrates mass gain beginning at 30% RH and reaching 5-8 wt% at 75% RH for the crystalline API. Manufacturing suites for tablet compression and capsule filling of cloxacillin sodium are therefore maintained at 35-45% RH and 18-22°C, with compressed air dried to -40°C dew point for pneumatic conveying and vacuum tube transfer systems. Failure to control humidity during direct compression produces sticking to punch faces, capping, and variable disintegration times.Binary compatibility screening via differential scanning calorimetry (DSC) and isothermal stress testing (40°C/75% RH, 4 weeks, open vials per ICH Q1A guidelines) has demonstrated compatibility with microcrystalline cellulose NF (PH 102 grade, 10-50 wt% loading), lactose monohydrate USP-NF as a crystalline diluent (20-60 wt%), croscarmellose sodium NF as a superdisintegrant (2-5 wt%), and magnesium stearate NF as a lubricant (0.5-1.0 wt%). Anhydrous dibasic calcium phosphate USP is contraindicated because surface-adsorbed moisture and alkaline surface pH (≥ 7.4) accelerate β-lactam ring hydrolysis, producing penicilloic acid degradants detected by HPLC at relative retention times of 0.3-0.6 versus the cloxacillin peak. Polyvinylpyrrolidone (PVP K30) as an aqueous binder at 3-5 wt% in wet granulation introduces process water, requiring subsequent drying at 45-50°C for 12-20 h in a fluidized bed dryer with inlet air dew point not exceeding -10°C.Tablet formulations for a 250 mg cloxacillin label strength are typically prepared by slugging or roller compaction of API with microcrystalline cellulose at a 1:1 to 1:2 ratio, followed by milling through a 0.8 mm screen on a FitzPatrick Model D6 hammer mill at 1,500 rpm. Final blends are compressed on a rotary tablet press at 10-15 kN compression force to achieve diametral hardness of 5-8 kp (Schleuniger Model 6D) and friability of 1.0-2.0% per USP <1216> (Copley friabilator, 100 revolutions). Tablet disintegration per USP <701> must be ≤ 15 min in water at 37°C. Dissolution testing per USP <711>, Apparatus 2 (paddle, 50 rpm) in 900 mL of pH 1.2 HCl (0.1 N) and pH 6.8 phosphate buffer, with sampling at 15, 30, 45, and 60 min, demonstrates 80-95% release from uncoated tablets at 30 min in pH 6.8 but limited release in pH 1.2 due to concurrent acid-catalyzed degradation.Cloxacillin sodium exhibits measurable degradation in simulated gastric fluid (pH 1.2, 37°C) with first-order half-life of approximately 20-40 min reported in antibiotic stability compendia. Oral tablets intended for systemic delivery are therefore film-coated with enteric polymers—Eudragit L 30 D-55 (methacrylic acid-ethyl acrylate copolymer) at 5-7% weight gain or HPMC-AS (hydroxypropyl methylcellulose acetate succinate) at 4-6% weight gain—applied in a perforated pan coater at 30°C inlet air temperature and 0.5-1.0 g/min/nozzle spray rate. Enteric coating integrity is verified by two-stage dissolution per USP <711>: 2 h in pH 1.2 followed by pH 6.8. Coated tablets must release ≤ 10% in the acid stage and ≥ 75% in the buffer stage within 45 min. Hard gelatin capsule formulations use size 1 or size 0 capsules filled on semi-automatic encapsulators at 30,000-60,000 capsules/h. The powder blend for capsules requires a repose angle ≤ 35° per USP <1174> flowability classification, achieved by adding 1.0-2.0% colloidal silicon dioxide (Aerosil 200) and 1-5% pregelatinized starch. Fill weight variability per USP <905> must not exceed ± 6.0% for 250 mg fill weight in capsules.

Excipient	Function	Loading Range	Compatibility Observation	Analytical Method
Microcrystalline cellulose NF (PH 102)	Binder/diluent	10-50 wt%	No exothermic deviation, no new HPLC peaks	DSC; HPLC USP <621>
Lactose monohydrate USP-NF	Crystalline diluent	20-60 wt%	Stable; Maillard reaction not observed with β-lactam	Isothermal 40°C/75% RH, 4 wks
Croscarmellose sodium NF	Superdisintegrant	2-5 wt%	Stable; promotes rapid disintegration	Disintegration USP <701>
Magnesium stearate NF	Lubricant	0.5-1.0 wt%	Stable up to 1.0%; higher levels slow dissolution	Dissolution USP <711>
Dibasic calcium phosphate USP	Diluent	Not recommended	Alkaline pH ≥ 7.4 accelerates β-lactam hydrolysis	Forced degradation HPLC
PVP K30	Wet granulation binder	3-5 wt%	Compatible; requires low-dewpoint drying	LOD USP <731>

Oral powder dosage-form conversion of cloxacillin sodium into water-soluble granules for group medication of poultry and swine proceeds from the API's exceptionally high aqueous solubility—approximately 1 g dissolves in 0.9 mL of water at 20°C—which enables drinking water medication at therapeutic concentrations of 200-500 mg cloxacillin per liter without solubility-limiting precipitation. The principal manufacturing challenge is not solubility but aqueous chemical stability after reconstitution on the farm. Dissolved cloxacillin sodium undergoes metal-ion-catalyzed degradation in the presence of Fe²⁺, Fe³⁺, Cu²⁺, and Zn²⁺ at concentrations as low as 0.5-1.0 ppm, levels commonly encountered in farm water supplies drawn from galvanized piping or groundwater wells. Formulation with chelating agents—edetate disodium (EDTA) at 0.5-1.0 wt% of API or citric acid at 2-5 wt%—sequesters divalent and trivalent metal ions and stabilizes the reconstituted medicated water solution for 24 h at ambient temperature, compared with 4-6 h for unbuffered API alone in controlled water stability studies.Dry powder sachets for oral solution use are manufactured by wet granulation in a high-shear mixer with impeller speed 250-400 rpm and chopper speed 1,500-3,000 rpm. The granulating binder is a 5% w/v PVP K30 aqueous solution added at 12-18% of dry powder mass. Granules are dried in a fluidized bed dryer at 55-60°C to a loss-on-drying per USP <731> of 1.0-2.0% w/w and milled through a 1.0 mm sieve. Target granule size distribution permits not more than 40% retained on a 500 µm sieve and not more than 30% passing a 150 µm sieve per USP <811> sieve analysis. This distribution optimizes both flowability with a Carr's Index of ≤ 20% and rapid dissolution achieving ≥ 95% drug release in 5 min in 500 mL water at 25°C per USP <1236>. Mixing uniformity for bulk powders is validated by sampling at 10 points during V-blender mixing at 25 rpm for 20 min with 60% fill volume; the acceptance criterion is a relative standard deviation of cloxacillin content ≤ 5.0% across all sampling points per the FDA Guidance for Industry on Powder Blends and Finished Dosage Units. Sachet fill weight verification uses in-line checkweighers at 60-120 sachets/min with ±3% reject limits. Sachet material is an aluminum/polyethylene laminate with moisture vapor transmission rate ≤ 0.1 g/m²/24 h at 38°C/90% RH per ASTM F1249-20. Oral powders for water medication fall under EU Regulation 2019/6 (Veterinary Medicinal Product Regulation) Article 116 for medicated water prescription, and packaging must include graduated measuring devices calibrated in grams of cloxacillin sodium per dose.

When Cloxacillin Sodium Premix Encounters Pelletizing Thermal Stress

Premix production for medicated feed application in swine and poultry involves geometric dilution of cloxacillin sodium API into inert carriers to produce homogeneous intermediate mixtures at concentrations of 1-10 wt% active. Carrier selection directly affects downstream feed-processing stability. Calcium carbonate (limestone flour, 325 mesh, D50 15 µm) and wheat middlings (D90 850 µm) are the most frequently used carriers, with ground rice hulls selected when dust liberation during open transfer operations must be minimized. Carrier oil coating with 1-2% mineral oil or soybean oil is applied to reduce API dust emissions during material handling and to improve dispersion kinetics during subsequent feed mixing. Geometric dilution validation for a 5% premix begins by blending 25 kg cloxacillin sodium with 25 kg carrier in a 100 L ribbon blender for 3-5 min, followed by stepwise quantity doubling through 50 kg, 100 kg, 200 kg, 400 kg, and 500 kg total batch mass. Mixing uniformity at each geometric stage is verified by near-infrared (NIR) spectroscopy with partial least-squares (PLS) calibration models delivering R² ≥ 0.98 and root mean square error of prediction < 0.5 wt%. Final premix must meet FDA Center for Veterinary Medicine Type A medicated article specifications with coefficient of variation for active content ≤ 8% per 21 CFR 558.3(b)(2).Cloxacillin sodium is labile under the thermal and moisture conditions of steam conditioning and pellet extrusion. Feed pelleting processes operate at 70-85°C with 12-16% added steam moisture for 30-90 s, generating conditions that produce measurable β-lactam degradation. Published stability data for penicillins in pelleted feeds indicate recovery losses of 15-40% after pelleting at 80°C for 2 min. Consequently, cloxacillin sodium premixes are not incorporated pre-pelleting but are applied post-pelleting by spray-on liquid suspension or by top-dressing the pellet cooler discharge with dry premix. Post-pelleting liquid application uses a suspension of cloxacillin sodium in food-grade soybean oil at a concentration of 50 mg/mL, sprayed onto pellets at 0.5-2.0% pickup ratio, achieving distribution coefficient of variation ≤ 10% across pellet surface as verified by solvent extraction and HPLC. Stability of cloxacillin sodium in dry feed matrices (corn-soybean based, 12% moisture) at 25°C/60% RH is documented at 90% potency retention after 90 days for post-pellet-applied product. At 40°C/75% RH, degradation accelerates with approximately 20% potency loss at 30 days, consistent with first-order kinetics having an apparent activation energy of 55-65 kJ/mol for β-lactam hydrolysis extrapolated from accelerated stability chamber data per VICH GL3. Feed containing cloxacillin must therefore carry moisture content ≤ 14% per AOAC 930.15 and be stored in vapor-barrier bags. Incompatibility: cloxacillin sodium premixes must never be blended with chlortetracycline or oxytetracycline premixes due to pH-induced precipitation of tetracycline salts and accelerated degradation of both antibiotic classes in the presence of divalent calcium ions derived from limestone carriers.

Manufacturing Route	Sterility Class	Endotoxin Limit	Controlled Environment	Primary Regulatory Anchor
Intramammary infusion	Sterile, USP <71>	≤ 0.5 EU/syringe	Grade A fill, isolator VHP	21 CFR 211 Subpart G; EU GMP Annex 1
Injectable powder	Sterile, USP <71>	≤ 0.5 EU/mg (IM)	Grade A fill, lyophilization	EU GMP Annex 1; USP <85>
Tablet/capsule	Non-sterile	Not applicable	RH 35-45%, 18-22°C	USP <711>, <905>
Oral powder/granule	Non-sterile	Not applicable	RH ≤ 50%, 55-60°C drying	EU Reg 2019/6; USP <811>
Premix	Non-sterile	Not applicable	Ambient, moisture ≤ 14%	21 CFR 558.3(b)(2); 21 CFR 225
Oral solution (reconstituted)	Non-sterile	Not applicable	RH ≤ 50% for powder filling	USP <795>; ISO 8317:2024

Reconstituted oral solutions of cloxacillin sodium for neonatal calves, lambs, and goat kids are dispensed as dry powders that are reconstituted at point of use, because aqueous solutions of cloxacillin sodium lack adequate chemical stability for commercial distribution as ready-to-use liquids over the required shelf life. The reconstitution vehicle is potable water buffered to pH 6.5 with sodium citrate dihydrate (0.1 M) to maintain the API within its optimum stability window, or 0.9% Sodium Chloride Solution USP for sterile presentations. Preservative systems for multi-dose bottles include methylparaben NF 0.18% and propylparaben NF 0.02%, confirmed compatible with cloxacillin sodium by HPLC assay after 30 days at 25°C/60% RH with no new degradant peaks exceeding 0.2% peak area. Single-dose presentations omit preservatives entirely but must be consumed within 2 h of reconstitution to limit microbial proliferation risk.Packaging for reconstituted oral cloxacillin solutions uses amber Type III soda-lime-silica glass or high-density polyethylene (HDPE) bottles with fill volumes from 100-500 mL, equipped with child-resistant closures per ISO 8317:2024 when dispensed through retail veterinary pharmacy channels. Reconstituted solutions stored at 2-8°C retain ≥ 90% potency for 10-14 days based on stability protocols sampling at 0, 3, 7, 10, and 14 days with potency determination by HPLC per USP <621>. Storage at 25°C shortens the beyond-use period to 3 days. Freezing is contraindicated: frozen aqueous cloxacillin sodium solutions undergo phase-separation-induced local pH shifts, and upon thawing may exhibit visible precipitation of the free acid, which is sparingly soluble in water at pH < 5. Oral solution dosing in calves is 10-20 mg cloxacillin base per kg body weight administered twice daily by drench or nipple bottle, based on pharmacokinetic parameters showing Tmax at 1-2 h, Cmax of 1.5-3.0 µg/mL at 15 mg/kg, and elimination half-life of 1.5-2.5 h in normal young ruminants. Dosing syringes or graduated cups calibrated to 5 mL increments are supplied with each bottle. Acute oral toxicity per OECD 423 indicates a wide therapeutic margin for β-lactams, with no mortality observed at 10 times the recommended dose, but labeling must still carry the withdrawal statement per 21 CFR 201.142 for food-producing species.